Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis

Next Previous
Trial Profile

CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenicriviroc (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms CENTAUR
  • Sponsors Allergan; Tobira Therapeutics

    • Most Recent Events

    • 16 Jun 2020 Results characterizing the metabolic effects of cenicriviroc (CVC), a potent CCR2/5 inhibitor, in type 2 diabetes mellitus (T2DM) patients with nonalcoholic steatohepatitis (NASH) fibrosis presented at the 80th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jan 2020 Results reporting data from the final year of the 2-year study published in the Hepatology
    • 18 Jul 2019 According to European Clinical Trials Registry record, Canada, Israel, Moldova and Romania were in planned location.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top